MaxCyte Inc. (MXCT) exhibits 96.0% gross margins and -27.1% return on invested capital within Health Care (Biotechnology: Commercial Physical & Biological Resarch), balanced against a 24.0x enterprise multiple and 4.8% implied options volatility.
Sustained 96.0% gross profitability converts into -60.0% operating margin and -27.1% ROIC, outpacing sector cost of capital.
ROIC: -27.1% // GM: 96.0%YoY revenue trajectory of -5.7% paired with -20.26% free cash flow yield supports self-funded R&D and capital return.
REV YOY: -5.7% // FCF YLD: -20.26%Altman Z-Score of 1.52 and Piotroski F-Score of 3/9 indicate low near-term refinancing stress.
ALTMAN Z: 1.52 // F-SCORE: 3/9Trading at 24.0x trailing P/E (— Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.0x // EV/EBITDA: —Options market prices a ±5.2% implied move with a 0.85 put/call ratio around $1.73 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Commercial Physical & Biological Resarch require continuous execution to defend -60.0% net margins.
NET MARGIN: -60.0% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for MXCT & activate live FRED threshold breach alerts.